Lisata Therapeutics Inc (LSTA)

[Rogerthat1]

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 16, 2017, at the 2017 Annual Meeting of Stockholders (the "Annual Meeting") of Caladrius Biosciences, Inc. (the "Company"), the stockholders voted on and approved the seven proposals listed below. The following is a brief description of each matter voted upon at the Annual Meeting (for a full description of each such matter see the Company's proxy statement), as well as the final voting results with respect to each such matter:

Proposal 1 . The stockholders approved the adoption of the interest purchase agreement (the "Purchase Agreement"), dated as of March 16, 2017, by and among the Company., PCT, LLC, a Caladrius Company ("PCT") and Hitachi Chemical Co. America, Ltd. ("Hitachi"), pursuant to which Hitachi will acquire from the Company the 80.1% interest in PCT that it does not own for $75.0 million in cash, subject to adjustment as described in the Proxy Statement. The final voting results with respect to this Proposal were as follows: 4,951,229 votes for; 155,736 votes against; 102,708 votes abstaining and 2,020,256 broker non-votes